---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-316916"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-07-27T12:00:16+00:00"
generated_at: "2026-07-27T12:05:38.027138+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kyverna signs commercial manufacturing deal with ElevateBio for miv-cel; BLA on track for Q4 2026

## Summary
- Agreement covers U.S. commercial and global clinical supply of miv-cel, replacing prior clinical deal.
- Supports potential launches in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG).
- Rolling BLA submission for miv-cel in SPS remains on track for Q4 2026.
- ElevateBio achieved >98% clinical manufacturing success rate for miv-cel.
- Initial five-year term with automatic renewals; minimum purchase commitments and annual PPI-based price adjustments.

## SEC filing metadata
- accession: 0001193125-26-316916
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-07-27T12:00:16+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526316916/0001193125-26-316916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526316916/kytx-20260723.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-316916
- JSON: https://secwatch.observer/filing/0001193125-26-316916.json
- Plain text: https://secwatch.observer/filing/0001193125-26-316916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.